All News

DAPSA PsA measure

Pathways to a Psoriatic Arthritis Diagnosis

d Jack Cush, MD

Ogdie and colleagues have retrospectively analyzed a longitudinal cohort of psoriatic arthritis (PsA) patients, showing that only two-thirds of PsA are diagnosed by rheumatologists, PCPs and dermatologists, with significant differences in what preemptive symptoms were noted by different subspecialties.

Read Article
RA,hand,elderly,active

Malnutrition and Quality of Life in Elderly RA Patients

d Jack Cush, MD

Rheumatoid arthritis (RA) imparts a significant disabilty and quality of life (QoL) limitations worsened by aging, but also by malnutrition.

Read Article
exhaustion,depression

Lupus Frailty Index Predicts Organ Damage

d MedPage Today

Patients with longstanding systemic lupus erythematosus (SLE) who were considered frail were more likely to accrue disease damage over time, a secondary analysis of data from a Chicago lupus cohort found.

Read Article
knee2_0.JPG (keep)

AAOS Clinical Practice Guideline for Knee Osteoarthritis

d Jack Cush, MD

The American Academy of Orthopaedic Surgeons has published their Clinical Practice Guideline for Management of Osteoarthritis of the Knee (Non-Arthroplasty); updating 19 of the 29 evidence-based recommendations and focuses on nonsurgical treatmentss to provide pain and patient function.

Read Article
We are at that time of year when rheumatology fellowship programs across the nation are exploring potential candidates to train. We share tips for both the interviewer and candidates on the blog today. https://t.co/eWQs9CwqSm https://t.co/iHeuQpsoQx

Links:

Dr. John Cush RheumNow ( View Tweet)
Lessebo effect: 31 RCT comparing Biologic originator to a biosimilar or to PBO: Lessebo effx =better responses in Biosimilar vs PBO (ACR20=70%) than w/ originator vs PBO (ACR20=59%). ? due to PBO effx in active comparator, nocebo in PBO trials https://t.co/kvANomTHrb

Links:

Dr. John Cush RheumNow ( View Tweet)

Beliefs translate to effects - ‘it will work’ (Placebo), ‘it will hurt’ (Nocebo); but now a "Lessebo" effect; neither benefit nor harm; instead a lower effect based on comparator. TNFi vs PBO has smaller effx (sup trial) than Biosimilar vs PBO (equiv) https://t.co/onyIkILqT9

Links:

Dr. John Cush RheumNow ( View Tweet)

Drug Safety Risk Communication- The 800 lb Gorilla Approach https://t.co/6iSJjvlFF8 https://t.co/mPeJfWi1hY

Links:

Dr. John Cush RheumNow ( View Tweet)
ASK CUSH ANYTHING! Rheums: Have a question for Dr. Cush? Record it here and we may feature it on an upcoming podcast. #RheumNow https://t.co/wzNmOzH4VE https://t.co/KzPzWpSoW1

Links:

Dr. John Cush RheumNow ( View Tweet)
Metabolic syndrome (MetS) is associated with radiographic & nodal hand OA (HOA). 896 MetS positive & 1613 w/o MetS assessed w/ propensity matching. MetS had more xray HOA ((OR 1.32), PIPs (OR 1.52), DIPs (1.38), hand pain (1.25)https://t.co/aNEV5b6Tmv

Links:

Dr. John Cush RheumNow ( View Tweet)

Malnutrition and Quality of Life in Elderly RA Patients https://t.co/4hEFTSaCga https://t.co/OPK3ThWqst

Links:

Dr. John Cush RheumNow ( View Tweet)
Patients with longstanding systemic lupus erythematosus (SLE) who were considered frail were more likely to accrue disease damage over time, a secondary analysis of data from a Chicago lupus cohort found. Read more on #RheumNow https://t.co/jQt5mFrMtS https://t.co/HljgqdKZtH

Links:

Dr. John Cush RheumNow ( View Tweet)
The AAOS has published their Clinical Practice Guideline for Management of Osteoarthritis of the Knee (Non-Arthroplasty); updating 19 of the 29 evidence-based recommendations and focuses on nonsurgical treatmentss to provide pain and patient function. https://t.co/faLi0X840d https://t.co/8iZkNEFkRy

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 380 nonintubated severe COVID-19 pneumonia patients showed that those with the highest tertiles of FERRITIN (1322-13 ,418) showed significant reduction in mortality (HR, 0.16; 0.06-0.45) if given methylprednisolone [120-240] mg https://t.co/Jr1aWlPpOk

Links:

Dr. John Cush RheumNow ( View Tweet)

Secukinumab (IL-17 inhibitors) can be safely used in HIV spondyloarthritis patients. https://t.co/hpCRJkR9w7

Links:

Dr. John Cush RheumNow ( View Tweet)

EHR record study: prevalence of Psoriatic arthritis (#PsA) was increased w/ psoriasis severity. PsA prevalence=2.9 per 100 PY; Based on severity - Mild 2.1/100PY; Moderate 9.9/100PY & severe PSO: PsA risk was 17.6/100PY https://t.co/hXeA773KN4 https://t.co/AUIYZiSq5k

Links:

Dr. John Cush RheumNow ( View Tweet)
Novel study of Pain Reprocessing Therapy;PRT in Chronic Back Pain. 151 pts w/ 10 yrs of LBP: 4 wk results - better w/ PRT (66%) (were pain-or nearly pain-free) vs PBO (20%) vs Usual care (10%), with gains maintained through 1-year follow-up https://t.co/lioI99GP80

Links:

Dr. John Cush RheumNow ( View Tweet)

NEJM Clinical Images: Sweets syndrome (Acute Febrile Neutrophilic Dermatosis) - 46F w/ raised painful lesions on extremities. https://t.co/up5PviNDeS)

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: New data from the CDC shows that obesity rates have risen in the USA during the pandemic, with 16 states having obesity rates of 35% or higher - that's four more than last year, adding Delaware, Iowa, Ohio and Texas to the list. https://t.co/9nFuea2BOV https://t.co/XmsXmFXhzv

Links:

Dr. John Cush RheumNow ( View Tweet)
POETYK PSO-1 and PSO-2 trial results seen at the EADV meeting, studying Tyk2 inhibitor, deucravacitinib vs PBO or apremilast in 666 & 1020 plaque psoriasis pts. Wk 16 PASI 75 higher in DEUC ((59%, 54%) vs Otezla (35%, 40%) vs PBO(13%,9%) https://t.co/qok68Kbb6J

Links:

Dr. John Cush RheumNow ( View Tweet)

×